GenomeFi, a specialized Web3 Blockchain and AI platform providing Decentralized Identity (DID) services based on individual genetic characteristics using NFTs, has acquired a business license and a free zone license within the Dubai Multi Commodities Center (DMCC) in Dubai, UAE.

Using AI technology, GenomeFi facilitates genetic information-based NFTs to provide identity verification services reflecting individual genetic characteristics. It aims to expand the ecosystem where DID services and genomic information are available across the spectrum, from genomics to biotechnology. GenomeFi also seeks to establish an incentive system using blockchain technology and encourage mass adoption of genomic content.

The GenomeFi Foundation, along with its core partner CLINOMICS, provides genomic medical solution services through the world’s best Genome-based diagnostic kits, monitors early diagnosis of cancer/disease through liquid biopsy and multi-omics technology, and provides personalized prescriptions, and personalized treatment services. Starting with Clinomics, a key partner, the expansion and popularization of medical services through cooperation with various medical institutions and medical companies can be used in real life by lowering accessibility through distributed ledger technology and Web 3.0, and participants in the GenomeFi ecosystem can receive services.

GenomeFi plans to intensify its business expansion in Dubai, based on networking and cooperative relationships with DMCC member companies.

In addition to collaborating with Web3 companies in Dubai, GenomeFi will focus on realizing a proof-of-concept business model that bridges the blockchain and medical industries through collaboration with genome-based medical centers.

Jimmy Choi, CEO of GenomeFi, stated, “Acquiring the DMCC license will strengthen our position in the Middle Eastern market based on Dubai and lay the groundwork for expanding our partners. We are preparing to conduct collaborative projects in various parts including investment, marketing, medical, on-chain, and community.”